Retrophin (RTRX) Upgraded at BidaskClub

BidaskClub upgraded shares of Retrophin (NASDAQ:RTRX) from a sell rating to a hold rating in a report published on Thursday.

Several other equities research analysts have also commented on RTRX. Zacks Investment Research upgraded shares of Retrophin from a strong sell rating to a hold rating in a research note on Wednesday, February 27th. Svb Leerink reiterated an outperform rating on shares of Retrophin in a research note on Tuesday, February 26th. ValuEngine lowered shares of Retrophin from a strong-buy rating to a buy rating in a research note on Thursday, January 17th. Nomura assumed coverage on shares of Retrophin in a research note on Monday, November 19th. They set a buy rating and a $57.00 price objective on the stock. Finally, TheStreet lowered shares of Retrophin from a c- rating to a d+ rating in a research note on Friday, February 22nd. Two investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Retrophin presently has a consensus rating of Buy and an average target price of $48.00.

Shares of NASDAQ:RTRX opened at $22.87 on Thursday. Retrophin has a 52 week low of $19.77 and a 52 week high of $33.00. The company has a market capitalization of $947.12 million, a price-to-earnings ratio of -9.00 and a beta of 1.02. The company has a current ratio of 4.74, a quick ratio of 4.68 and a debt-to-equity ratio of 0.61.

Retrophin (NASDAQ:RTRX) last announced its quarterly earnings results on Tuesday, February 26th. The biopharmaceutical company reported ($0.21) EPS for the quarter, beating the consensus estimate of ($0.63) by $0.42. Retrophin had a negative net margin of 62.51% and a negative return on equity of 33.53%. The company had revenue of $43.77 million for the quarter, compared to analyst estimates of $43.54 million. During the same quarter last year, the business earned $0.07 earnings per share. Retrophin’s revenue was up 3.8% compared to the same quarter last year. Sell-side analysts predict that Retrophin will post -2.54 EPS for the current year.

In related news, SVP Elizabeth E. Reed sold 1,500 shares of the firm’s stock in a transaction that occurred on Wednesday, January 9th. The shares were sold at an average price of $23.96, for a total transaction of $35,940.00. Following the transaction, the senior vice president now owns 17,077 shares in the company, valued at $409,164.92. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP William E. Rote sold 1,250 shares of the firm’s stock in a transaction that occurred on Tuesday, February 19th. The shares were sold at an average price of $21.52, for a total transaction of $26,900.00. The disclosure for this sale can be found here. Insiders have sold 45,418 shares of company stock worth $996,877 in the last quarter. Company insiders own 3.67% of the company’s stock.

Institutional investors have recently bought and sold shares of the business. MetLife Investment Advisors LLC grew its position in Retrophin by 55.7% in the third quarter. MetLife Investment Advisors LLC now owns 29,333 shares of the biopharmaceutical company’s stock worth $843,000 after buying an additional 10,491 shares during the last quarter. Handelsinvest Investeringsforvaltning grew its position in Retrophin by 33.8% in the fourth quarter. Handelsinvest Investeringsforvaltning now owns 66,916 shares of the biopharmaceutical company’s stock worth $1,514,000 after buying an additional 16,916 shares during the last quarter. Jane Street Group LLC acquired a new position in Retrophin in the third quarter worth approximately $2,296,000. Russell Investments Group Ltd. grew its position in Retrophin by 17.1% in the third quarter. Russell Investments Group Ltd. now owns 233,527 shares of the biopharmaceutical company’s stock worth $6,706,000 after buying an additional 34,150 shares during the last quarter. Finally, Wells Fargo & Company MN grew its position in Retrophin by 16.1% in the third quarter. Wells Fargo & Company MN now owns 110,585 shares of the biopharmaceutical company’s stock worth $3,177,000 after buying an additional 15,335 shares during the last quarter.

About Retrophin

Retrophin, Inc, a biopharmaceutical company, focuses on the development, acquisition, and commercialization of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, and for adjunctive treatment of patients with peroxisomal disorders; and Thiola, a tiopronin tablet for the treatment of cystinuria.

Read More: Trading Ex-Dividend

Analyst Recommendations for Retrophin (NASDAQ:RTRX)

Receive News & Ratings for Retrophin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply